Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.

Name: Αlpha¹ Rigor Record — Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
Item: Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
Rating: 59
Author: Αlpha¹

Cooke GS, Hung LM, Flower B, McCabe L, Hang VTK, Thu VT, Thuan DT, Dung NT, Phuong LT, Khoa DB, An NTC, Thach PN, Huong VTT, Bich DT, Tuyen NK, Ansari MA, Le Ngoc C, Quang VM, Phuong NTN, Thao LT, Tran NB, Kestelyn E, Kingsley C, Van Doorn R, Rahman M, Pett SL, Thwaites GE, Barnes E, Day JN, Chau NVV, Walker AS

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 2 high issues for “Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsStatistic did not reproduce−0.5★
IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced4 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions overstated beyond the evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and thoroughly reported randomised controlled non-inferiority trial. The design is rigorous, ethical approvals are documented, and statistical methods are appropriate. Minor reporting gaps include threshold p-values, lack of explicit CONSORT statement, and absence of code sharing, but these do not undermine the overall integrity.

Both reviewers agreed on study type and all dimension statuses. The statistics verification component checked only 2 tests (1 consistent, 1 not flagged as error), so the statistical analysis is not fully verified. The citation check found no retracted or missing references. The claim audit flagged one overstated claim about cost-saving, which is addressed in the action items.

7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT).

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites WHO guidelines and notes the lack of randomised trials comparing the two regimens, establishing the need for the study. The rationale for testing novel strategies is supported by the need to expand access to treatment. Limitations of prior research are implicitly addressed by the trial design, though not explicitly detailed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work, identifying a gap in head-to-head comparisons, and providing a logical rationale for the study objectives.

Evidence

direct quote[Introduction, paragraph 1]

“No randomised trials have compared these treatment combinations and, in the absence of head-to-head comparisons and with high variability in generic pricing, countries differ in their choice of first-line treatment.”